AU757975B2 - Therapeutic compounds - Google Patents

Description

WO 99/38869 PCT/AU99/00062 I THERAPEUTIC COMPOUNDS This invention relates to novel structural analogues and derivatives of compounds with general analgesic or related pharmacological activity. In particular the invention relates to derivatives of opioid compounds, particularly morphine and related compounds.

BACKGROUND OF THE INVENTION A large range of therapeutic compounds is currently used in the treatment of conditions such as allergies, diarrhoea, migraine and other pain conditions, and in the treatment of congestive heart failure. These compounds include compounds with analgesic or related activities, such as anti-tussives, anti-depressants, local anaesthetics, anti-hypertensives, anti-asthmatics, antihistamines, and anti-serotonins.

However, many of the therapeutic compounds of the types enumerated above have undesirable side-effects, such as the respiratory depression caused by opiates. In particular, many drugs which are useful for their action on the peripheral nervous system have undesirable effects in the central nervous system.

Thus opiates are the most powerful analgesics known, but their usefulness is greatly limited by their side-effects, including severe respiratory depression, and ability to induce addiction and physical dependence.

Despite intensive efforts to design analogues of morphine and related opioids which retain the analgesic activity but which do not have a deleterious effect on the central nervous system and the bowel, success has been limited. Structure-activity relationships have been extensively investigated, and a number of features have been widely accepted as essential. See for example "An Introduction to Pharmacology" by J.J. Lewis S.

Livingston Ltd, 1964 Pages 401-407), and "Principles of Drug Action: The Basis of Pharmacology (Ed. W.B. Pratt and WO 99/38869 PCT/AU99/00062 2 P.Taylor; Churchill Livingstone, 3 rd edition, 1990, Pages 25-27). In particular, it is generally considered that to retain analgesic activity the group on the tertiary nitrogen should be small, and should preferably be methyl; larger substituents are likely to be opiate receptor antagonists rather than agonists. Thus replacement of the methyl group of morphine by an allyl or cyclopropylmethyl moiety produces an antagonist. Although there are isome.

exceptions to this rule, such as N-amylnormorphine and N-hexylnormorphine, in general a large substituent will result in antagonist activity.

We have attempted to modify the ability of biologically-active compounds to cross the blood-brain barrier by incorporating a highly polar group into the molecular structure. Thus we have shown that derivatives of the 2N atom of mianserin comprising a guanidino group show H 1 and 5-hydroxytryptamine activity, but show no detectable activity in the central nervous system. In contrast, a compound in which the 2N atom of mianserin was substituted with a urea group still showed pronounced central nervous system activity (Jackson et al; Clin. Ex.

Pharmacol. Physiol., 1992 19 17-23 and our U.S. Patent No.

5,049,637).

Naltrexamine and oximorphamine have been modified by incorporation of groups which are zwitterionic at biological pH in order to restrict access to the central nervous system (Botros et al; J. Med. Chem., 1989 32 2068- 2071, and Portoghese, U.S. Patent No. 4,730,048). In US- 4,730,048 the zwitterionic group was added at C6. Some of these analogues were full agonists, and one was a strong antagonist.

A bis(t-butyldimethylsiloxy)-substituted compound in which a guanidino derivative was attached to the nitrogen via a 3 carbon spacer chain was found to show no opioid activity at g-receptors in isolated guinea-pig ileum (Jackson et al, 1992). This suggested that such compounds would not have the desired activity.

08/01 '03 MON 11:10 FAX 61 3 9243 8333 GRIFFITH HACK 004 3 Therefore there is a need for therapeutic compounds which have less activity within the central nervous system, thus having fewer undesirable side-effects, whilst at the same time having greater specificity of action on peripheral physiological mechanism. We have found that several compounds with the general formula outlined below not only have reduced central side-effects, but retain activity at desired peripheral receptors. In particular, those compounds which show activities at opioid receptors retain broad analgesic activity, contrary to current orthodoxy which teaches that the analgesic effects of opioids are mediated from the CNS. Their selectivity for peripheral opioid receptors not only makes them useful for the treatment of pain without sedative or addictive effects, but also may make them useful for treatment of AIDS and related immune deficiency diseases.

SUMMARY OF THE INVENTION In the broadest aspect, the invention provides an opioid compound of formula I YN-X-[amidine or guanidine group],

I

in which YN is an organic residue obtained by removal of the group on the nitrogen atom of an opioid; and X is a direct bond or a spacer group, or a pharmaceutically acceptable salt thereof, where said compound has activity at opiate receptors.

For the purposes of this specification, the term "opioid compound" is to be taken to mean a compound structurally related to morphine.

The group X is either a direct bond or a spacer group. The spacer can be any spacer group of dimensions approximately equivalent to an alkyl chain of 1 to 6 carbon HI \vaulad\KcciD\ncci\24037-99 AMlEMIMEE...daoc 2/01/03 4 atoms, and may for example be a straight or branched alkyl, alkenyl or alkenyl chain of 1 to 6 carbon atoms, which may optionally be substituted. The -spacer may also comprise a cyclic alkyl, alkenyl or alkynyl group. Preferably the spacer group is unsubstituted, and more preferably is of 2 to 3 carbon atoms. The amidine or guanidine group is a "charged group" in the sense that at physiological pH the group has the ability to restrict access of the compound of formula I to the central nervous system. The term "amidine or guanidine group" is used in the broadest sense to refer to any amidine or guanidine groups, and not just those containing hydrogen atoms on each of the nitrogens in the group.

According to one embodiment, the present S 15 invention provides an opioid compound of general formula (II) ee z YN-(CH2)n- (NH)o or 1 c R2 in which 20 YN- represents an organic residue obtained by removal of the R group from an opioid compound of general formula YN-R (IIIa) wherein R is H, alkyl of 1 to 6 carbon atoms, cyclopropylmethyl, PhCH 2

CH

2 or Me 2 C=CHCh 2 Z is NR 3

R

1 is HI, alkyl or aryloxyalkyl, wherein the aryl group is optionally substituted by alkyl, alkoxy, halogen, or alkyl substituted by halogen, and alkyl, alkoxy and the alkyl moiety of aryloxy alkyl have 1 to 6 carbon atoms; H:\pau1ad\Keep\speci\24037-99 AMENOMENTSdoc 19/12/02 5

R

2 is H or an alkyl group having 1 to 6 carbon atoms;

R

3 is H, alkyl, hydroxy, amino, cyano or acyl, wherein alkyl and acyl have 1 to 6 carbon atoms; n is 0 or an integer of 1 to 6, and wherein R and R may together complete an addition ring; in which case the grouping

C

\/R2 N R1 may become a heterocyclic moiety such as 2-imidazolyl or 2-imidazolinyl: N N or R2 R2 Preferably R is CH 3 Preferably n is 2 or 3.

Preferably Z is NH, and R 1 and R 2 are both H.

S 20 In order to indicate the trivalent N-atom more clearly, the structure of compounds of the formula (IIIa) may be written Y N-R (IIIc) The precursors of YN- are selected from compounds which are structurally related to morphine.

Thus the precursor of YN- is preferably a compound selected from the group consisting of morphine, H:\pau1ad\Keep\speci\2437-99 AMENDMENTS.doc 19/12/02 -6 codeine, heroin, ethylmorphine, 0-carboxymethyrnorphine, 0acetylmorphine, hydrocodone, hydromorphone, oxymorphone, oxycodone, dihydrocodeine, thebaine, metopon, etorphine, acetorphine, ketobemidone, ethoheptazine, diprenorphine (M5050), buprenorphine, phenomorphan, levorphanol, pentazocine, eptazocine, metazocine, ethoheptazine, ketobemidone, dihydroetorphine and dihydroacetorphine.

Preferably the precursor is morphine, codeine or buprenorphine.

In a preferred embodiment, the compound of general formula I is one of the following: HO HO *NH 0,71

N

N NH,

*NH,

KRS-41 KR S-2-19 MeO ~NH ,,NH o.P4'.j

NH

2 j MeO MeO HO--7M HO -Me Me Me KR S-3-28 KR S-3-23-4 H:\pauad\Keepspeci\24037-99 AMENDKENTS.doc 19/12/02 WO 99/38869 WO 9938869PCT/AU99/00062 -7 HO >Me Me KRS-3-30-2 KRS-3-56 KRS-2-47 KRS-2-63

NH

/W N F Me Me KRS-4-8 KRS-3-7 Typical examples of morphine-related compounds of the formula (Ila) or (IlIc) are illustrated in Table 1.

In each case the group R has been circled in order to clearly identify the residue YN- or Y 1 NR 4 as the remainder of the molecule.

WO 99/38869 PCT/AU99/00062 8 The preferred precursors also include the unnamed compounds whose structures are shown in Table 1, with the nitrogen atom at position 17 indicated.

2" 06/01 '03 MON 11:11 FAX 61 3 9243 8333 RFIH AKII00 GRIFFITH RACK [a 005 9- Table 1 Compounds with Analgesic or Related Type Activity and Some Related Structures R X 2 Name

CH

3 H H morphine CH3 H Codeine Et H Ethylmorphine Ac Ac Heroin

CH

2 C00H H 0-Carboxymethylmorphine Ac H 0-Acetylmorphine tBuMe 2 Si t~uMe 2 Si "Disilyl" morphine H tBuMe 2 Si tluMe 2 Si I"Disilyl" normorphine R X -or R R R N'ame

CH

3 H H H Et Etorphine Ac H H Et Acetorphine H H H Et Dihydroetorphine.

Ac H H Et Dihydroacetorphine C2- H H H H Diprenorphine H CH 3

,CH

3

,CH

3 Buprenorphine II;\ u.A\e-\6ei2079 A~fMENM=S.doc 2tft/03 10 C- R 0 R CH 3

CH

2

O

Ethoheptazine

X-

1 X- X Name

OH

3 H H Hydrocodone H H H Hydrornorphone H OH H Oxymorphone

OH

3 OH H Oxycodone H IH O H 3 IMetopon R Name PhOH 2

CH

2 Phen omorphan CH3 Levorphanol HO 0 Ketobemidone R X Name

OH

3 H Eptazocine Me 2

O=OHCH

2

OH

3 Pentazocine O H 3

OH

3 Metazocine

CH

3 1 OH I (Y

OCH

3 Thebaine Dihydrocodeine 11 Thus the invention provides in a second broad aspect an opiate receptor agonist having analgesic properties and having reduced or no CNS activity.

Preferably the opiate receptor agonist is a compound of general formula I or general formula II as defined above.

Where appropriate, the invention also includes pharmaceutically acceptable salts of the compounds of formula I, or formula,II. A variety of pharmaceuticallyacceptable salt-forming organic and inorganic acids is well known in the art.

According to third aspect, the invention provides a method of reducing the central nervous system activity of an opioid compound, comprising the step of linking the nitrogen atom of said compound to an amidine or guanidine 15 group, optionally via a spacer group. For many of the opioids exemplified, the nitrogen atom is at the 17position, but for others such as eptazocine, the nitrogen atom is at a differently numbered position, but corresponds to the 17-position of morphine.

According to a fourth aspect of the invention, S' methods for the preparation of the compounds of formula II are provided, as set out below: 1. By the reaction of a compound of formula 25 YN- (CH 2 (NH) ori-H (IV) with a cyanamide, R1NHCN 2. By the reaction of a compound of formula (IV) with a compound of formula

SNR

3 L-C (V) NR

R

2 wherein L is a suitable leaving group, for Sexample CH30, CH 3 S, CH 3

SO

2 SO3H or H:\pau1ad\Keep\speci\2437-99 AMIENMENTS.doc 19/12/02 12 CH3 N

N-

S (3,5-dimethylpyrazol-1-yl) CH3 Compounds of the formula (II) wherein Z is S not only possess useful therapeutic activity per se, but may also be used as intermediates for the preparation of 2 compounds of formula II wherein Z is NR 2 eg.

3. By the reaction of a compound of the formula 10 YN(CH 2

(NH)

0 or 1 -CN (VI) with H 2 S there is obtained an N-thiocarboxamide,which may be reacted with an amine R R2NH to yield compounds of the invention where Z is NH.

4. The N-thiocarboxamide may also be methylated, for example using CH 3 I, to yield an isothiourea compound, which in turn may be reacted with an amine R R2NH to yield a compound of the invention.

5. An alternative method of synthesis of compounds of formula (II) comprises reacting an N-cyano compound of formula (VI) with methanol under acidic conditions to yield an isourea, which in turn is reacted with an amine R R NH to yield a compound of the present invention in which R 3 is H.

6. Compounds according to formula (II) where Z is NH may also be prepared, for example from the N-cyano compound of formula (VI) and the appropriate metallated residue (for example, sodamide NaNR'R 2 or metallated amines such as Me AICINR R 2 or BrMgNR R2).

H:\paulad\Keep\speci\24037-99 A4ENfMENTS.doc 19/12/02 13 7. Compounds of the formula most of which are also novel, and which are useful as intermediates in reactions 3, 5 and 6 above, can be prepared by reacting a compound of formula (III) (see Table 1) with cyanogen bromide in a hydrocarbon solvent: YN-R BrCN YN-CN 8. Compounds of general formula which are useful as intermediates in reactions 1 and 2, can be prepared from the compounds of formula (III) (Table 1) by the following reactions: YN-R C13CCH20OCOC1 -4 YN-CO.OCH 2 CC13 ft

C

et H:\pau1ad\Keep\speci\24O37-99 AMENDMENTS.doc 19/12/02 WO 99/38869 PCT/AU99/00062 14 Zn/AcOH YN-COOCH2CCI 3

YN-H

Some compounds of the invention are optically active, and it will be clearly understood that both racemic mixtures and isolated stereoisomers are within the scope of the invention.

According to a fifth aspect, the invention provides a composition comprising as-an effective agent a compound according to formula I, together with a pharmaceutically acceptable carrier.

Methods and pharmaceutical carriers for preparation of pharmaceutical compositions are well known in the art, as set out in textbooks such as Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Company, Easton, Pennsylvania,

USA.

According to a sixth aspect, the invention provides a method of inducing analgesia, comprising the step of administering an effective amount of a compound of the invention to a mammal in need of such treatment. The mammal may be a human, or may be a domestic, companion or zoo mammal. Preferably the mammal is a human.

The dosage to be used will depend on the nature and severity of the condition to be treated, and will be at the discretion of the attending physician or veterinarian.

The most suitable dosage for a specific condition can be determined using normal chemical trial procedures.

For the purposes of this specification it will be clearly understood that the word "comprising" means "including but not limited to", and that the word "comprises" has a corresponding meaning.

Brief Description of the Figures Figure 1 shows dose-response curves for morphinelike activity in guinea-pig stimulated ileum preparations, using morphine as standard: a) Compounds KRS-3-28 and KRS-3-30-2 (4 animals in each group); SUBSTITUTE SHEET (Rule 26) (RO/AU) WO 99/38869 PCT/AU99/00062 15 b) Compounds KRS-41 and KRS-2-19.

c) Compound KRS-3-56 (3 animals in each group).

DETAILED DESCRIPTION OF THE INVENTION The invention will now be described in detail by way of reference only to the following non-limiting examples, and to the Figures.

Example 1 Preparation of N-Cyano Compounds, YN-CN A solution of YN-R (0.02 mole of the base) in anhydrous benzene (20 ml) was added slowly to a stirred solution of cyanogen bromide (2.3 g) in anhydrous benzene ml) in an atmosphere of nitrogen. After 24 hours, the mixture was diluted with diethyl ether (50 ml) and shaken with water (50 ml). The separated aqueous layer was back extracted with a mixture of benzene and ether (equal volumes of each, total 50 ml) and the combined organic layers dried over anhydrous potassium carbonate and then evaporated under reduced pressure. The residual solid was recrystallized from ethanol to give the N-cyano derivative YN-CN as colourless needles.

NH

II

Example 2 Preparation of Carboxamidines,

YN-C-NH

2 A solution of sodamide in liquid ammonia was prepared in the usual way from metallic sodium (0.35 g) in dried liquid ammonia (150 ml) in the presence of a trace of ferric nitrate. The reaction mixture was kept at about 0 C and moisture was rigorously excluded. The N-cyano derivative YN-CN (0.01 mol) was then added slowly, and the mixture stirred whilst dried hexamethylphosphorictriamide (HMPA) was added dropwise until the N-cyano compound began to dissolve; about 1 ml of HMPA was required. A deep brown solution was formed. The stirring was continued for 30 minutes and the solution poured cautiously into a solution of ammonium chloride (4 g) in iced water (150 ml).

The resulting suspension was kept for some 30 minutes at SUBSTITUTE SHEET (Rule 26) (RO/AU) WO 99/38869 PCT/AU99/00062 16 room temperature and the solid then filtered off and washed with a little water. The residue was reserved. The combined filtrate and washings were concentrated in vacuo to about 25 ml, when a second crop of solid separated.

The two crops and were combined and recrystallized from isopropanol to give the carboxyamidine hydrochloride

NH

II

YN-C-NH

2 .HC1 as'the colourless solid. Example 3 Preparation of Thiocarboxamido Derivatives,

YN-CSNH

2 Dry hydrogen sulphide was passed through a solution of the N-cyano compound YN-CN (500 mg) in a mixture of triethylamine (0.25 ml) and pyridine (25 ml) for 24 hours. The resulting solution was poured into water (150 ml) and the mixture stirred for 30 minutes at room temperature to afford colourless crystals which were filtered off, washed with fresh water and dried in in vacuo. Recrystallization from a mixture of diethyl ether and light petroleum gave colourless needles of the desired compound.

Example 4 Preparation of Carboxoamido Derivatives,

YN-CONH

2 A slurry of the N-cyano compound YN-CN (0.02 moles) in aqueous hydrogen peroxide (100 Vol., 0.51 ml) and 20% aqueous sodium hydroxide (0.51 ml) was stirred for 30 minutes, during which time the reaction mixture became warm, then cooled to room temperature; some oxygen was evolved. Three portions of methanol (3 x 2 ml) were added to the reaction mixture, at 30 minute intervals with stirring. The mixture was warmed to 60 0 C for minutes, then poured into water (50 ml) to give a white precipitate which was filtered at the pump, washed with water (2 x 10 ml) and dried in vacuo to give the N-carboxamido derivative YN-CONH 2 as a colourless solid.

WO 99/38869 PCT/AU99/00062 17 Example 5 Preparation of 3,6-bis(t-butyldimethylsiloxy)-7,8-didehydro-4,5-epoxymorphinan (3,6c-Bis[dimethyl(1,1-dimethylethyl)siloxy 7,8-didehydro-4, Dry, alcohol-free dichloromethane (100 ml) was added to a flask containing normorphine (5.42 g, 20 mmol), t-butyldimethylsilyl chloride (6.62 44 mmol),:imidazole (6:.12 g, 90 mmol), and 4-dimethylaminopyridine (120--mg, 1.0 mmol). After 20 hours of stirring at room temperature, the reaction mixture was diluted with ether (200 ml), washed with water (3 x 200 ml), dried (Na 2

SO

4 and evaporated to give a grey-yellow solid (10.11 g).

Recrystallization from ethanol gave very fine grey needles (5.20 g, m.p. 105.7-107.0 0 C. The mother liquors were recrystallized (ethanol, twice) to give a second crop (2.45 g, m.p. 105.0-106.7 0 C. A small portion of the first crop was recrystallized again to give m.p. 106.2- 107.2 0

C.

Example 6 Preparation of 3,6-bis(t-butyldimethylsiloxy)-7,8-didehydro-4,5-epoxy-17methylmorphinan (O,O'-Bis-tbutyldimethylsilyl-morphine) Ref: Neuvo, J. Chim. 1980 4 369-375 Solid t-butylchlorodimethylsilane (3.8 g, mmol) was added to a stirred solution of morphine g, 10.5 mmol) and imidazole (3.6 g, 52.9 mmol) in dimethylformamide (DMF; 20 ml) under a nitrogen atmosphere.

Stirring of the reaction mixture was continued at room temperature for 2 hours, then the mixture was heated to 900 for 4 hours. The mixture was poured into water (25 ml) then extracted into dichloromethane (3 x 25 ml), dried

(K

2

CO

3 and evaporated to give a yellow oil, which crystallised on addition of a small amount of methanol.

Recrystallisation from methanol gave colourless needles m.p. 118-1190C (Lit 119-119.5°C) (5.02 g, 93%).

WO 99/38869 PCT/AU99/00062 18 Example 7 Preparation of 3,6-bis(t-butyldimethylsiloxy)-7,8-didehydro-4,5-epoxy-17-N-cyanomorphinan A solution of bis-silylmorphine (7.0 g, 1.36 mmol) in dry benzene (50 ml) was added dropwise to a stirred solution of cyanogen bromide (2.9 g, 27.4 mmol) in dry benzene.under-a. nitrogen atmosphere. :;The stirred solution was refluxed for 4 hours, allowed to cool to room temperature, then evaporated. The solid residue was purified by rotary chromatography (Si02: 5% ethanol in chloroform), then crystallisation from methanol to give 3,6-bis(t-butyldimethyl-siloxy)-7,8-didehydro-4,5-epoxy-17- N-cyano-morphinan (6.3 g, 86%).

Example 8 Preparation of O,0'-bis-t-butyldimethylsilyl- N-thiocarboxamidonormorphine Cyanamide (524 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) were dissolved in dry pyridine (20 ml).

Dry hydrogen sulphide gas was slowly bubbled through the stirred pyridine solution for 4 hours, then the mixture was poured into water (100 ml), extracted into dichloromethane (3 x 20 ml), washed with water (3 x 20 ml), dried with MgSO 4 and evaporated. Recrystallisation from methanol gave colourless needles of the required O,O'-bis-tbutyldimethylsilyl-N-thiocarboxamidonormorphine (490 mg, 88%).

Example 9 Preparation of 3,6-bis(t-butyldimethylsiloxy)-7,8-didehydro-4,5-epoxy-17-(Ncarboxamidino)-morphinan Ref: Ravi S. Garigipati, Tetrahedron Letters, Vol 31, No 14, pp 1969-1972, 1990.

J. I. Levin, E. Turos and S.M. Weinrub, Synthetic Communications, 12, 989-993, 1982.

A solution of 3,6-bis(t-butyldimethylsiloxy)-7,8didehydro-4,5-epoxy-17-N-cyano-morphinan (100 mg.

WO 99/38869 PCT/AU99/00062 19 0.19 mmol) in dry benzene (2 ml) was added to a solution of methylchloroaluminium amide (prepared according to the Weinrub procedure) in benzene at room temperature. This solution was heated at 80 0 C under nitrogen for 20 h. The reaction mixture was cooled, and the aluminium complex was decomposed by carefully pouring the solution into a slurry of silica gel (2.0 g) in chloroform. The mixture was stirred for-.5-minm and filteredi.x The--filter cake was; washed with methanol (50 mL). Evaporation of the filtrate gave a white solid (0.106 which was used in the next step without further purification.

Example 10 Preparation of (5a,6a)-7,8-didehydro-4,5epoxy-17-N-(2-carboxamidino)-morphinan-3,6,diol. (KRS-2-19) Ref: R. Newton, D.Reynolds, M. Finch, D.

Kelly, S. Roberts, Tetrahedron Letters, No 41, 3981-82, 1979.

A slurry of 3,6-bis(t-butyldimethylsiloxy)-7,8didehydro-4,5-epoxy-17-(N-carboxamidino-morphinan (106 mg, 0.19 mmol) in 10:1 mixture of acetonitrile and tetrahydrofuran was cooled in an ice bath, and 40% aqueous HF (0.2 mL) was added dropwise. After stirring overnight at room temperature the reaction mixture was concentrated under reduced pressure to give a light yellow solid, which was passed through a short silica gel column using methylene chloride/methanol in 8:2 ratio as the eluent to give KRS-2-19 as a white solid (0.64 g, 98%).

Example 11 Alternative Preparation of 3,6-bis(tbutyldimethylsiloxy)-7,8-didehydro-4,5epoxymorphinan Normorphine, prepared according to Chemical Abstracts, Vol. 54, 162f, (100 mg, 0.36 mmol) was dissolved in dry DMF (0.5 mL) and imidazole (0.0628 g, 0.92 mmol) and dimethylaminopyridine (0.07 g) was added. t-Butyldimethylsilyl chloride was then added in small amounts at room WO 99/38869 PCT/AU99/00062 20 temperature. After the addition was complete the reaction mixture was stirred at room temperature under nitrogen while being monitored by thin layer chromatography. After 10-15 min distilled water was added and the reaction mixture was extracted with methylene chloride. The methylene chloride layer was dried over potassium carbonate and evaporated under reduced pressure to give crude product, which was purified by column :chromatography on silica gel using methylene chloride/methanol/ammonium hydroxide in 9:1:0.1 ratio as the eluent. (Yield 120 mg, Example 12 Preparation of 3,6-bis(t-butyldimethylsiloxy)-7,8-didehydro-4,5-epoxy-17-(N-2cyanoethyl)morphinan Ref: J.A.Bell and C. Kenworthy, Synthesis, 650-652, 1971.

3,6-Bis(t-butyldimethylsiloxy)-7,8-didehydro-4,5epoxymorphinan (0.26 g, 0.52 mmol) was dissolved in absolute ethanol (3 mL) and acrylonitrile (0.07 ml, mmol) was added dropwise at room temperature. The reaction mixture was stirred at room temperature overnight, and the solvent was evaporated under reduced pressure to give a white solid (0.26 g, 90% yield).

Example 13 Preparation of 3,6,bis(t-butyldimethylsiloxy)-7,8-didehydro-4,5-epoxy-17-N-[(2aminoiminomethyl)ethyl]morphinan A solution of 3,6-bis(t-butyldimethylsiloxy)-7,8didehydro-4,5-epoxy-17-(N-2-cyanoethyl) morphinan (0.257 g, 0.46 mmol) in dry benzene (5 mL) was added to a solution of methylchloroaluminum amide in benzene at room temperature.

The solution was heated at 80 0 C under nitrogen for 20 h.

This was worked up as before to give a white solid (0.157 which was used for the next step without further purification.

WO 99/38869 PCT/AU99/00062 21 Example 14 Preparation of (5a,6a)-7,8-didehydro-4,5epoxy-17-N-[(2-aminoiminomethyl)ethyl]morphinan-3,6-diol. (KRS-41) The crude 3,6,bis(t-butyldimethylsiloxy)-7,8didehydro-4,5-epoxy-17-N[(2-aminoiminomethyl)ethyl]morphinan was deprotected using 40% HF in 10:1 mixture of acetonitrile and tetrahydrofuran as described before. The product.was triturated with ethylacetate. and with: methanol.

The remaining white precipitate was recrystallized with ethanol and water to give KRS-41 as a white powder (90 mg) in 94% yield.

Example 15 Preparation of N-carboxamidino-7a-(l-hydroxy- 1-methylethyl)-6,14-endo-ethenotetrahydronorthebaine (KRS-3-7) N-Cyano-7a-(l-hydroxy-l-methylethyl)-6,14-endoethenotetrahydronorthebaine was prepared according to the method of Bentley and Hardy, J. Amer. Chem. Soc., 1967 89 3281-3292. This compound was reacted with methylchloroaluminum amide in benzene as described before.

The crude product was purified by column chromatography on silica gel using methylene chloride/methanol/ammonium chloride in 6:1:0.1 ratio as the eluent to give KRS-3-7 as a white solid (56 mg. 91% yield).

Example 16 Preparation of N[(2-aminoiminomethyl)ethyl]- 7a-(l-hydroxy-l-methylethyl)-6,14-endoethenotetrahydronorthebaine (KRS-3-28) 7a-(l-Hydroxy-l-methylethyl)6,14-endoethenotetrahydronorthebaine, prepared according to the method of Bentley and Hardy (1967) op. cit., was converted to the corresponding N-2-cyanoethyl compound in 96% yield by reacting with acrylonitrile in absolute ethanol.

N-2-Cyanoethyl-7a-(l-hydroxy-l-methylethyl)-6,14endo-ethenotetrahydronorthebaine was then reacted with methylchloroaluminum amide in benzene as described above.

The crude product was purified by column chromatography on WO 99/38869 PCT/AU99/00062 22 silica gel using methylene chloride/methanol/ammonium chloride in 9:1:0.1 ratio as the eluting solvent to give KRS-3-28 (125 mg, 45 yield).

Example 17 N-Carboxamidino-7a- (l-hydroxy-l-methylethyl) 6,14-endo-ethenotetrahydro-nororipavine

(KRS-

3-23-4) S3-O-Acetyl-7a-(l-hydroxy-l-methylethyl)-6,-714-.....

endo-ethenotetrahydrooripavine, prepared according to the method of Bentley and Hardy, op.cit., was reacted with cyanogen bromide in dry methylene chloride to give acetyl-N-cyano-7a-(l-hydroxy-l-methylethyl)-6,14-endoethenotetrahydronororipavine in 97% yield. This compound was then reacted with methylchloroaluminum amide in benzene as described above. The crude product was purified by column chromatography on silica gel using methylene chloride/methanol/ammonium chloride in 6:1:0.1 ratio as the eluting solvent to give KRS-3-23-4 as a white solid (102 g, 34% yield).

Example 18 N-Carboxamidino-7a-(1-hydroxy-l-methylethyl)- 6,14-endo-ethanotetrahydro-oripavine (KRS-3- 30-2) 7a-(l-Hydroxy-l-methylethyl)-6,14-endoethanotetrahydro-oripavine was prepared by the method of Lewis, "Narcotic Antagonists", in Advances in Biochemical Psychopharmacology, 1974 8 123-136, Raven Press, New York. The 3-O-acetyl ester was prepared by the addition of acetic anhydride to a solution of the phenol in aqueous sodium hydroxide, and was obtained as a white solid. The 0-acetyl ester was then reacted with cyanogen bromide in dry chloroform to give N-cyano-nororipavine derivative in 70% yield, which was then reacted with methychloroaluminum amide in benzene. The crude product was purified by column chromatography on silica gel using methylene chloride/methanol/ammonium hydroxide in 9:1:0.1 WO 99/38869 PCT/AU99/00062 23 ratio. KRS-3-30-2 was obtained as a white powder in yield.

Example 19 N-(N'-carboxamidino-3-aminopropyl)-7-(1hydroxy-l-methylethyl)-6,14-endoethenotetrahydronororipavine (KRS 3-56) a) Preparation of N-2-cyanoethyl-7a-(l-hydroxy-lmethylethyl) -6,14 endo-ethenotetrahydronororipavine.

7a-(l-Hydroxy-l-methylethyl)-6,14-endoethenotetrahydronororipavine was prepared according to the method of K.W. Bentley and D.G. Hardy, Journal of the American Chemical Society, 1967 89 3281-3292. This compound was reacted with acrylonitrile in absolute ethanol as described. The crude product was purified by column chromatography on silica gel using methylene chloride/ethyl acetate/methanol in 4:4:1 ratio as the eluent.

b) Preparation of 3-(t-butyldimethylsiloxy)-N-2cyanoethyl-7a-(1-hydroxy-1-methylethyl)-6,14-endoethenotetrahydro-nororipavine Solid t-butyldimethylsilyl chloride (0.035 g, 0.227 mmol) was added in small amounts to a stirred solution of N-2-cyanoethyl-7a-(l-hydroxy-l-methylethyl)- 6,1 4 -endo-ethenotetrahydronororipavine (80 mg, 0.189 mmol), imidazole (0.015 g, 0.227 mmol) and 4-dimethylaminopyridine (0.005 g) in anhydrous dimethylformamide (0.5 ml) under a nitrogen atmosphere. After stirring for lh at room temperature distilled water (10 ml) was added to the reaction mixture and the mixture was extracted with methylene chloride. The organic layer was dried over potassium carbonate and evaporated under reduced pressure.

The solid formed was purified by column chromatography on silica gel, using ethyl acetate/X4 in 1:1 ratio as the eluent. (Yield 79 mg, 78%) WO 99/38869 PCT/AU99/00062 24 c) Preparation of 3-(t-butyldimethylsiloxy)-N-(3aminopropyl) -7a- (1-hydroxy-l -methylethyl) -6,14-endoethenotetrahydro-nororipavine.

3-(t-butyldimethylsiloxy)-N-2-cyanoethyl-7a-(1hydroxy-l-methylethyl)-6,14-endo-ethenotetrahydronororipavine (100 mg, 0.186 mmol) in dry ethyl ether (2 ml) was added dropwise to lithium aluminium hydride (0.008 g, 0.223 mmol) in dry ether After .stirring for. 3:.h at room temperature wet ether followed:by 10% NaOH (1 ml) was added to the reaction mixture. The solution was filtered and the white precipitate was washed with ether. The ether layer was evaporated under reduced pressure to give the amine as a white solid (99 mg, 98%).

d) Preparation of 3-(t-butyldimethylsiloxy)-N-(Ncarboxamidino-3 -aminopropyl) 7- (1 -hydroxy-1 -methylethyl) 6,14-endo-ethenotetrahydronororipavine Ref: Michael S. Bernatowicz, Youling Wu and Gary R. Matsueda, Journal of Organic Chemistry, 1992 57 2497- 2502 To a mixture of 3-(t-butyldimethylsiloxy)-N-(3aminopropyl)-7a-(l-hydroxy-l-methylethyl)-6,14-endoethenotetrahydronororipavine (0.196 g, 0.37 mmol), diisopropylethylamine (0.065 ml, 0.37 mmol) and 1Hpyrazole-l-carboxamidine hydrochloride (0.055 g, 0.37 mmol) was added anhydrous dimethylformamide (2 ml), and the reaction mixture was stirred at room temperature under nitrogen for overnight. The reaction mixture was evaporated to dryness under reduced pressure, and the crude product was chromatographed on silica gel.

(Yield 0.191 g, 88%).

e) Preparation of N-(N'-carboxamidino-3-aminopropyl)-7a- (1-hydroxy-1-methylethyl) -6,14-endo-ethenotetrahydronororipavine (KRS 3-56) HF (0.3 ml, 0.0065 mol) was added dropwise to 3-(t-butyldimethylsiloxy)-N-(N'-aminoiminomethyl- WO 99/38869 PCT/AU99/00062 25 aminopropyl)-7a-(l-hydroxy-l-methylethyl)-6,14-endoethenotetrahydronororipavine (0.191 g, 0.3 mmol) in 10:1 mixture of acetonitrile/tetrahydrofuran (10 ml), and the reaction mixture was stirred overnight at room temperature.

The white precipitate formed was filtered and was washed with acetonitrile and then with methanol to give KRS 3-56 as a white solid (0.135 g, 96%).

Example 20. 50,6a-7,8-didehydro-4,5-epoxy-3-methoxy-17-N- [(2-aminoiminomethyl)ethyllmorphinan (KRS-2- 63) a) Preparation of 7,8-didehydro-4,5-epoxy-17-(N-2cyanoethyl)morphinan-3, 6-diol Acrylonitrile (0.03 mL, 0.44 mmol) was added dropwise to normorphine (0.1 g, 0.37 mmol) in absolute ethanol (2 mL) at room temperature. The reaction mixture was stirred at room temperature overnight and the solvent was evaporated under reduced pressure. The crude product was chromatographed on silica gel using ethylacetate and hexane in 3:1 ratio as the eluent (yield 86 mg, 71%).

b) Preparation of 7,8-didehydro-4,5-epoxy-3-methoxy-17-(N- 2-cyanoethyl)morphinan-6-ol 7,8,-Didehydro-4,5-epoxy-17-(N-2-cyanoethyl)morphinan-3,6-diol (86 mg, 0.265 mmol) was suspended in dry acetone (2 mL), and anhydrous potassium carbonate (0.037 g, 0.27 mmol) was added, followed by methyl iodide (0.025 ml, 0.39 mmol). After refluxing for 5 h the solvent was evaporated under reduced pressure and the crude product was purified by column chromatography on silica gel using ethylacetate and hexane in 2:1 ratio as the eluting solvent (yield 70 mg, 78%).

c) Preparation of 6 -t-butyldimethylsiloxy-7,8-didehydro- 4, 5-epoxy-3-methoxy-17-(N-2-cyanoethyl)morphinan 7,8-Didehydro-4,5-epoxy-3-methoxy-17-(N-2cyanoethyl)morphinan-6-ol (50 mg, 0.15 mmol) was dissolved WO 99/38869 PCT/AU99/00062 26 in dry dimethylformamide (0.5 mL), and imidazole (11.1 mg, 0.16 mmol) and dimethylaminopyridine (20 mg) was added.

t-Butyldimethylsilyl chloride (24.1 mg, 0.16 mmol) was then added at room temperature under nitrogen atmosphere. After stirring for 2 h at room temperature, distilled water was added and the reaction mixture was extracted with methylene chloride. The methylene chloride layer was dried with :potassium carbonate and evaporated under reduced',pressure to give the crude product, which was purified by column chromatography on silica gel using ethylacetate/hexane in 3:1 ratio as the eluent (yield 50 mg, 73%).

d) Preparation of 6-t-butyldimethylsiloxy-7,8-didehydro- 4,5-epoxy-3-methoxy-17-N-[(2-aminoiminomethyl)ethyl]morphinan A solution of 6-t-butyldimethylsiloxy-7,8didehydro-4,5-epoxy-3-methoxy-17-(N-2-cyanoethyl)morphinan mg, 0.11 mmol) in dry benzene (2 mL) was added to a solution of methylchloroaluminum amide in benzene at room temperature. The solution was heated at 80 0 C under nitrogen for 20 h. The reaction mixture was worked up as before to give a light brown solid, which was purified by column chromatography on silica gel using methylene chloride/methanol/ammonia in 9:1:0.1 ratio to give the product as a white solid (yield 44 mg, e) Preparation of 5a, 6a-7, 8-didehydro-4, 5-epoxy-3methoxy-17-N-[(2-aminoiminomethyl)ethyl]morphinan (KRS-2-63) 6-t-Butyldimethylsiloxy-7,8-didehydro-4,5-epoxy- 3-methoxy-17-N-[(2-aminoiminomethyl-ethyl)morphinan (44 mg, 0.09 mmol) was dissolved in a mixture of acetonitrile and tetrahydrofuran (2.5 mL/0.25 mL) and the solution was cooled in an ice bath. To this 0.1 mL of 40% HF was added dropwise, and the mixture was stirred for 2 h at room temperature. The white precipitate formed was filtered and WO 99/38869 PCT/AU99/00062 27 washed with acetonotrile to give KRS-2-63 as the fluoride salt (yield 34 mg, 96%).

Example 21 N-(aminoiminomethylaminopropyl)-7-(1hydroxy-l-methylethyl)-6,14-endoethanotetrahydronororipavine (KRS-4-8) Preparation of N-cyanoethyl-7a-(1-hydroxy-lmethyl ethyl )-6,14-endo-ethanotetrahydronororipavine' 7 a-(l-Hydroxy-l-methylethyl) -6,14-endoethanotetrahydronororipavine was prepared according to the method of Lewis Lewis: Narcotic Antagonists, in Advances in Biochemical Psychopharmacology, Vol. 8 edited by M.C. Braude, L.S. Harris, E.L. May, J.P. Smith and J.E.Villarreal. Raven Press, New York 1974). This compound was reacted with acrylonitrile in absolute ethanol as described. The crude product was purified by column chromatography on silica gel using ethyl acetate/hexane in 1:1 ratio as the eluent.

Preparation of 3- (t-butyldimethylsiloxy) -N-cyanoethyl- 7a- (1-hydroxy-1-methylethyl)-6,14-endo-ethanotetrahydronororipavine N-cyanoethyl-7a-(l-hydroxy-1-methylethyl)-6,14endo-ethanotetrahydronororipavine was reacted with t-butyldimethylsilylchloride as described for KRS-3-56.

The crude product was purified by column chromatography on silica gel, using ethylacetate/hexane in 2:1 ratio as the eluent.

c) Preparation of 3-(t-butyldimethylsiloxy)-N-aminopropyl- 7a-(1-hydroxy-1-methylethyl) -6,14-endo-ethanotetrahydronororipavine 3-(t-butyldimethylsiloxy)-N-cyanoethyl-7a-(1hydroxy-l-methylethyl)-6,1 4 -endo-ethanotetrahydronororipavine (0.11 g, 0.204 mmol) in dry ethyl ether (2 ml) was added dropwise to a suspension of lithium aluminum hydride (0.093 g, 2.45 mmol) in dry ethyl ether (2 ml).

WO 99/38869 PCT/AU99/00062 28 After stirring for 3 h at room temperature, wet ether ml) followed by 10% sodium hydroxide (1 ml) was added to the reaction mixture. The solution was filtered, and the white precipitate was washed with ether. The filtrate was evaporated under reduced pressure to give the amine as a clear liquid (70 mg, 63%).

d) ,Preparation..of 3- (t-butyldimethylsiloxy)-N- (aminoiminomethylaminopropyl) -7a-(l-hydroxy-l-methylethyl) 14-endoethanotetrahydronororipavine Anhydrous dimethylformamide (0.5 ml) was added to a mixture of 3-(t-butyldimethylsiloxy)-N-aminopropyl-7-(1hydroxy-l-methylethyl)-6,14-endo-ethanotetrahydronororipavine (70 mg, 0.129 mmol), diisopropylethylamine (0.022 ml, 0.129 mmol) and 1H-pyrazole-l-carboxamidine hydrochloride (0.019 g, 0.129 mmol), and the reaction mixture was stirred overnight at room temperature under nitrogen. The solvents were evaporated under reduced pressure, and the crude product was chromatographed on silica gel (yield 57 mg, 76%).

e) Preparation of N-(aminoiminomethylaminopropyl)-7Q-(lhydroxy-methylethyl)-6,14-endo-ethanotetrahydronororipavine (KRS-4-8) 40% HF (0.2 ml, 0.004 mol) was added dropwise to 3-(t-butyldimethylsiloxy)-N-(aminoiminomethylaminopropyl)- 7a-(l-hydroxy-l-methylethyl)-6,14-endo-ethanotetrahydronororipavine (57 mg, 0.097 mmol) in a 10:1 mixture of acetonitrile/tetrahydrofuran (10 ml), and the reaction mixture was stirred overnight at room temperature. The white precipitate formed was filtered, and was washed with acetonitrile and then with methanol to give KRS-4-8 as the fluoride salt (44 mg, 96% yield).

WO 99/38869 PCT/AU99/00062 29 Example 22 Synthesis of (5a,6a)-7,8-didehydro-4,5-epoxy- 17-(N-aminoiminomethylaminopropyl)morphinan- 3,6-diol (KRS-2-47) Preparation of 3,6-bis(t-butyldimethylsiloxy)-7,8didehydro-4, 5-epoxy-17-aminopropylmorphinan A solution of 3,6-bis(t-butyldimethylsiloxy)-7,8didehydro-4,5-epoxy-17-cyanoethylmorphinan (200 mg, 0.36 mmol).in dry.ethyl -ether ml)i :was .added dropwise to asuspension of lithium aluminum hydride (0.13 g, 3.6 mmol) in dry ethyl ether (5 ml). After stirring for 3 h at room temperature the reaction mixture was added wet ether followed by 10% sodium hydroxide (1.5 ml). The solution was filtered, and the white precipitate was washed with ether. The ether layer was evaporated under reduced pressure to give the amine as a clear liquid (yield 0.2 g, 99%).

Preparation of 3, 6-bis(t-butyldimethylsiloxy)-7,8didehydro-4, 5-epoxy-17- (N-aminoiminomethylaminopropyl) morphinan Anhydrous dimethylformamide (2 ml) was added to a mixture of 3,6-bis(t-butyldimethylsiloxy)-7,8-didehydro- 4 ,5-epoxy-17-aminopropylmorphinan (0.2 g, 0.359 mmol), diisopropylethylamine (0.07 ml, 0.39 mmol), and 1H-pyrazole-l-carboxamidine hydrochloride (0.06g, 0.39 mmol) and the reaction mixture was stirred overnight at room temperature under nitrogen. The reaction mixture was evaporated to dryness under reduced pressure, and the crude product was chromatographed on silica gel (yield 0.155 g, 72%).

Preparation of (5a, 6a)-7, 8-didehydro-4,5-epoxy-17- (Naminoiminomethylaminopropyl morphinan-3, 6-diol (KRS-2-47) 3,6-bis(t-butyldimethylsiloxy)-7,8-didehydro-4,5epoxy-17-(N-aminoiminomethyl-aminopropyl)morphinan was deprotected using 40% HF in a 10:1 mixture of acetonitrile and tetrahydrofuran as described before. The precipitate WO 99/38869 PCT/AU99/00062 30 was filtered and washed with acetonitrile, methylenechloride followed by methanol. KRS-2-47 was obtained as a white powder in 73% yield (70 mg).

Example 23 Analgesic Activity We have found evidence that these compounds have analgesic activity by showing stereoselectivity for peripheral-..opioid..receptors Thus,,.c.l-ow subcutaneous or intraperitoneal doses of N-methylnalorphninium iodide (10-300 gg/kg) showed analgesic activity in the mouse test of Hendershot and Forsaith Pharmacol. Exp. Ther., 1959 125 237-240) and in the rat inflamed paw test of Randall and Selitto (Archs. Int. Pharmacodyn. Ther., 1957 111 409-419), whereas N-allylmorphinium iodide given in doses of 10 mg/kg was found to be inactive in both tests.

S-methyllisothiocarbamoyl norheroin iodide was also active in both tests after administration of doses of 1-3 mg/kg.

Compound KRS-41 (Example 16) was tested for analgesic activity in two mouse analgesia models. In the first test, the test substance was administered to groups of 5 ICR derived male mice weighing 22 2 g one hour before subplantar injection of formalin (0.02 ml, 1% solution). Reduction of the induced hind paw licking time recorded during the following 20 to 30 minute period by 50% or more indicates analgesic activity. Table 2 below shows that KRS-41 has analgesic activity at 3 times the morphine concentration, which is consistent with the relative opiate receptor activities discussed below in Example 23.

WO 99/38869 PCT/AU99/00062 31 Table 2 Treatment Reduction in Hind Paw Licking time Vehicle DMSO/saline) 0 Morphine HC1 (10 mg/kg) 100 KRS-41 (10 mg/kg) 12 KRS-41 (3'0 mg/kg) 75' In the second test, the test substance was administered to groups of 3 ICR derived male mice weighing 22 2 g 30 minutes before injection of PQ (2 mg/kg).

Reduction in the number of writhes by 50% or more per group of animals observed during the 5 to 10 minute period after PQ administration, relative to a vehicle treated control group, indicates analgesic activity. Table 3 below shows that KRS-41 has analgesic activity at 5 times the morphine concentration.

Table 3 Treatment Reduction in Writhes Vehicle DMSO/saline) 0 Morphine HC1 (3 mg/kg) 87, 73 (two tests) KRS-41 (3 mg/kg) 18 KRS-41 (15 mg/kg) 93 Example 24 Guinea Pig Stimulated Ileum Preparation Five compounds, KRS-41 (Example 16), KRS-2-19 (Example 12), KRS-3-28 (Example 18), KRS-3-30-2 (Example 20) and KRS 3-56 (Example 21) were tested for opiate activity in a standard guinea-pig stimulated ileum assay, using morphine as a standard.

Male Monash strain guinea-pigs were killed and the ileum removed. Segments (approxm. 1.5-2.5 cm) were WO 99/38869 PCT/AU99/00062 32 mounted on tissue holders with in-built stimulating electrodes, and set up in 5 ml isolated organ baths containing Krebs solution of the following composition (mM) NaCl 118.4; KC1 4.1; MgSO 4 .7H 2 0 1.2; KH 2 P0 4 1.2; NaHCO 3 25; glucose 11.1; CaC1 2 .2H 2 0 2.5. The Krebs solution was bubbled with carbogen (95% 02, 5% CO 2 and the preparations maintained at 370C under 1 gram resting tension. The.-tissues were stimulated transmurally using single pulses of 0.5 ms duration at 0.2 Hz and 40 V from a Grass SD9 stimulator, and allowed to equilibrate under these conditions before the addition of drugs.

Cumulative dose-response curves to morphine (using increments of a half log unit) were obtained before obtaining cumulative dose-response curves to the test compounds. The results are shown in Figure 1.

Surprisingly, KRS-41 showed excellent activity compared to morphine (Figure Ib). This compound has an aminoiminoethyl substituent on the tertiary N atom, and was expected to have either no activity or antagonist activity.

KRS-4-8 gave results similar to those observed with buprenorphine.KRS 3-56 (Figure 10) also showed even more striking activity, with a potency of approximately 6 times that of morphine, and was a full agonist of the g opiate receptor. KRS-2-47 is expected to give similar results.

Although KRS-3-28 had low potency compared to morphine, its activity in this assay is comparable to that of codeine. Codeine is metabolized in vivo to morphine, so its effect after oral administration is comparable to that of morphine given by injection. KRS-3-28 is expected to metabolize in similar fashion after oral administration or parenteral injection to give a buprenorphine-like compound.

In contrast, KRS-2-19 (Figure 16) and KRS-3-30-2 (Figure la) showed only partial morphine agonist activity.

It therefore appears that a spacer group in which n is 2 results in stronger opiate activity than a spacer in which n is 1.

WO 99/38869 PCT/AU99/00062 33 KRS-2-63 showed partial agonist activity, but would be expected to be converted in vivo by demethylase enzymes in the liver to KRS-41, in a similar manner to metabolism of codeine. Similar results would be expected for other compounds of the invention with a methoxy group at carbon 3.

Example 25., .)Effectof...KRS 3-56 and KRS-41 on the Central Nervous System .0 The effects of compounds KRS-3-36 and KRS-41 on the central nervous system were compared with that of morphine using a standard Irwin test (Irwin, S.; Psychopharmacologic (Berlin), 1968 13 222-257). The relevant results are shown in Tables 4 and Table 4 Test Vehicle Morphine 10 mg/kg Tail elevation 2.5 0.7 7.0 0.7 Respiratory rate 5.6 0.2 4.1 0.3 Positional Passivity 4.7 0.3 8.7 0.4 Grip strength 5.1 0.4 3.7 0.3 Corneal reflex 4.5 0.2 2.9 0.2 Table Test Vehicle KRS-41 KRS-3-56 mg/kg 3 mg/kg Tail elevation 4.4 0.2 2.0 0.4 2.4 0.4 Respiratory rate 5.1 0.2 5.1 0.2 5.4 0.2 Positional Passivity 4.7 0.2 4.7 0.3 5.4 Grip strength 5.0 0.3 5.1 0.4 5.1 0.2 Corneal reflex 4.9 0.1 4.9 0.1 4.8 0.1 WO 99/38869 PCT/AU99/00062 34 These results indicate that the compounds of the invention, while retaining the analgesic activity of morphine, are non-sedating and do not cause respiratory depression. It is believed that this results from exclusion of the compounds from the central nervous system.

It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification.

Claims (24)

1. An opioid compound of formula I YN-X-[amidine or guanidine group], S I in which YN is an organic residue obtained by removal of the group on the nitrogen atom of an opioid; and X is a direct bond or a spacer group, or a pharmaceutically acceptable salt thereof, where said opioid compound has activity at opiate receptors.

2. A compound according to Claim 1, in which the spacer is a straight or branched alkyl, alkenyl or alkenyl chain of 1 to 6 carbon atoms, which may optionally be substituted.

3. A compound according to Claim 1, in which the spacer is a cyclic alkyl, alkenyl or alkynyl group, which may optionally be substituted.

4. A compound according to any one of Claims 1 to 3, in which the spacer group is unsubstituted. A compound according to any one of Claims 1 to 4, in which the spacer group is of 2 to 3 carbon atoms.

6. A compound according to any one of Claims 1 to in which the opioid from which the organic residue YN- is derived is selected from the group consisting of morphine, codeine, heroin, ethylmorphine, O-carboxymethylmorphine, O-acetylmorphine, hydrocodone, hydromorphone, oxymorphone, oxycodone, dihydrocodeine, thebaine, metopon, etorphine, acetorphine, ketobemidone, ethoheptazine, diprenorphine (M5050), buprenorphine, phenomorphan, levorphanol, pentazocine, eptazocine, metazocine, ethoheptazine, ketobemidone, dihydroetorphine and dihydroacetorphine.

7. A compound according to Claim 1, of general formula (II) H:\paua1d\Kccp\3pcci\24037-BS AMENDMEITS.doa 2/01/03 36 S. S 5 S S Z or 1- C R2 in which YN- represents an organic residue obtained by removal of the R group from an opioid compound of general formula YN-R (IIIa) wherein R is H, alkyl of 1 to 6 carbon atoms, cyclopropylmethyl,PhCH 2 CH 2 or Me 2 C=CHCH 2 Z is NR 3 R 1 is Hi, alkyl or aryloxyalkyl, wherein the aryl 15 group is optionally substituted by alkyl, alkoxy, halogen, or alkyl substituted by halogen, and alkyl, alkoxy and the alkyl moiety of aryloxy alkyl have 1 to 6 carbon atoms; R 2 is H or an alkyl group having 1 to 6 carbon atoms; R 3 is H, alkyl, hydroxy, amino, cyano or acyl, wherein alkyl and acyl have 1 to 6 carbon atoms; n is 0 or an integer of 1 to 6, and wherein R 1 and R 3 may together complete a ring, or a pharmaceutically acceptable salt thereof.

8. A compound according to Claim 7, in which R 1 and R 3 together complete a ring, and the grouping -C R2 N R1 forms 'a heterocyclic moiety. H:\pauad\Keep\speci\24037-99 AMENDENTSdoc 19/12/02 37

9. A compound according to Claim 8, in which the heterocyclic moiety is a 2-imidazolyl or 2-imidazolinyl group of formula: or R2 R2 A compound according to Claim 8 or Claim 9, in which R is CH3.

11. A compound according to any one of Claims 8 to 10 10, in which n is 2 or 3.

12. A compound according to any one of Claims 8 to 11, in which Z is NH, and R 1 and R 2 are both H.

13. A compound according to any one of Claims 8 to 11, in which the precursor of YN- is a compound selected from the group consisting of morphine, codeine, heroin, ethylmorphine, O-carboxymethylmorphine, O-acetylmorphine, hydrocodone, hydromorphone, oxymorphone, oxycodone, dihydrocodeine, thebaine, metopon, etorphine, acetorphine, ketobemidone, ethoheptazine, diprenorphine (M5050), o 20 buprenorphine, phenomorphan, levorphanol, pentazocine, eptazocine, metazocine, ethoheptazine, ketobemidone, dihydroetorphine and dihydroacetorphine.

14. A compound according to Claim 13, in which the precursor of YN- is morphine, codeine or buprenorphine.

15. A compound according to Claim 1, in which the opioid compound of formula (IIIa) is selected from the group set out in Table 1.

16. A compound according to Claim 1, in which the compound of general formula I is selected from the group consisting of KRS-41, KRS-2-19, KRS-3-7, KRS-3-23-4, KRS-3-28, KRS-3-30-2, KRS-3-56, KRS-2-63, KRS-4-8, and KRS-2-47, as herein defined. H:\pauIad\Keep\speciA2437-99 AMENDMENTS.doc 19/12/02 38

17. An opiate receptor agonist having analgesic properties and having reduced or no CNS activity, of general formula I or general formula II as defined in any one of claims 1 to 16.

18. A method of reducing the central nervous system activity of an opioid compound, comprising the step of linking the nitrogen atom of said opioid compound to an amidine or guanidine group, optionally via a spacer group.

19. A method for the preparation of a compound of formula II as defined in any one of Claims 8 to 14, with the proviso that when n is an integer of from 1 to 6, (NH) is present, comprising the steps of Reacting a compound of formula 15 YN- (CH 2 (NH) or 1 -H (IV) with a cyanamide, R 1 NHCN, to yield a compound of formula II in which each of R 2 and R 3 are H; *or •*or Reacting a compound of formula (IV) with a compound of formula L-C (V) NRR wherein L is a leaving group, to form a compound of formula II. A method for the preparation of a compound of formula II as defined in any one of Claims 8 to 14 in which Z is NR 3 comprising the steps of H: \paulad\Keep\speci\24037-99 AMENDMENTS.doc 19/12/02 39 Reacting a compound of the formula YN-(CH 2 (NH) or 1 -CN (VI) with H 2 S to obtain an N-thiocarboxamide YN-(CH 2 )n-(NH)o or 1-CSNH 2 and either Reacting this product with an amine R 1 R 2 NH to form a compound of formula II in which R 3 is H, or (ii) Methylating the N-thiocarboxamide to yield S. an isothiourea compound, and in turn reacting the 15 isothiourea with an amine R 1 R 2 NH to yield a compound of formula II in which R 3 is H.

21. A method of synthesis of a compound of formula (II) as defined in any one of Claims 8 to 14, comprising the step of reacting an N-cyano compound of formula (VI) as defined in Claim 19 with methanol under acidic conditions *to yield an isourea, and in turn reacting the isourea with an amine HNR 1 R 2 to yield a compound of formula II in which R 3 is H.

22. A method of synthesis of a compound of formula (II) as defined in any one of Claims 8 to 14 in which R 3 is H, comprising the step of reacting an N-cyano compound of formula (VI) as defined in Claim 19, with a metallated residue containing -NR'R 2 to form a compound of formula II.

23. A composition comprising a compound according to any one of Claims 1 to 16, together with a pharmaceutically acceptable carrier.

24. A method of inducing analgesia, comprising the step of administering an effective amount of a compound H:\pauad\Keep\speci\2437-99 AMENDMENTS.doc 19/12/02 CO 0009 C C. *C*C C ego, .CoS So C 00 CO 40 according to any one of Claims 1 to 16 to a mammal in need of such treatment. A method according to claim 23 in which the mammal is a human.

26. Use of a compound according to any one of Claims 1 to 16 in medicine.

27. Use of a compound according to any one of Claims 1 to 16 for the manufacture of a medicament for inducing analgesia.

28. A compound, composition, method or use substantially as herein described with reference to the Examples. SH:\paulad\Keep\speci\ 2 40 37 -99 AMENDMENTS.doc 19/12/02 o o 0050 C C go* ooo o go o o o C eeoC o g 00